Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
View/ Open
Author
Novak, Peter
Galica, Andrew
Roberson, Paula
Craft, Suzanne
Abduljalil, Amir
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.2337/dc13-1672Metadata
Show full item recordCitation
Novak, Vera, William Milberg, Ying Hao, Medha Munshi, Peter Novak, Andrew Galica, Bradley Manor, Paula Roberson, Suzanne Craft, and Amir Abduljalil. 2014. “Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes.” Diabetes Care 37 (3): 751-759. doi:10.2337/dc13-1672. http://dx.doi.org/10.2337/dc13-1672.Abstract
OBJECTIVE To determine acute effects of intranasal insulin on regional cerebral perfusion and cognition in older adults with type 2 diabetes mellitus (DM). RESEARCH DESIGN AND METHODS This was a proof-of-concept, randomized, double-blind, placebo-controlled intervention evaluating the effects of a single 40-IU dose of insulin or saline on vasoreactivity and cognition in 15 DM and 14 control subjects. Measurements included regional perfusion, vasodilatation to hypercapnia with 3-Tesla MRI, and neuropsychological evaluation. RESULTS Intranasal insulin administration was well tolerated and did not affect systemic glucose levels. No serious adverse events were reported. Across all subjects, intranasal insulin improved visuospatial memory (P ≤ 0.05). In the DM group, an increase of perfusion after insulin administration was greater in the insular cortex compared with the control group (P = 0.0003). Cognitive performance after insulin administration was related to regional vasoreactivity. Improvements of visuospatial memory after insulin administration in the DM group (R2adjusted = 0.44, P = 0.0098) and in the verbal fluency test in the control group (R2adjusted = 0.64, P = 0.0087) were correlated with vasodilatation in the middle cerebral artery territory. CONCLUSIONS Intranasal insulin administration appears safe, does not affect systemic glucose control, and may provide acute improvements of cognitive function in patients with type 2 DM, potentially through vasoreactivity mechanisms. Intranasal insulin-induced changes in cognitive function may be related to vasodilatation in the anterior brain regions, such as insular cortex that regulates attention-related task performance. Larger studies are warranted to identify long-term effects and predictors of positive cognitive response to intranasal insulin therapy.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931384/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351358
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)